Pure Global
NCT04444141

A Study of PD-1/CTLA-4 Bispecific AK104 in Relapsed or Refractory Peripheral T-cell Lymphoma

A Multicenter, Open-label, Phase Ib/II Study of AK104, a PD-1/CTLA-4 Bispecific Antibody, in Subjects With Relapsed or Refractory Peripheral T Cell Lymphoma
Akeso·Phase 1/2·ClinicalTrials.gov·biologicalRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Peripheral T-cell Lymphoma
Drug/Device/Intervention
AK104
Study type
Interventional
Intervention type
biological
Sponsor & location
Primary sponsor
Akeso
Location
Beijing, China
Timeline & enrollment
Phase
Phase 1/2
Start date
May 15, 2020
End date
Jun 30, 2022
Enrollment
80 participants
Primary outcome

Objective response rate (ORR)

Summary

The purpose of this study is to evaluate the efficacy and safety of AK104，an anti- PD-1 and
 CTLA-4 bispecific antibody, in subjects with relapsed or refractory peripheral T cell
 lymphoma. The subject will receive AK104 450mg Q2W until unacceptable toxicity, confirmed
 disease progression, withdrawal of consent, or for a maximum of 24 months.

ICD-10 classifications
Peripheral T-cell lymphoma, not elsewhere classifiedCutaneous T-cell lymphoma, unspecifiedMature T/NK-cell lymphomasAngioimmunoblastic T-cell lymphomaOther mature T/NK-cell lymphomas
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT04444141
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT04444141 through Pure Global AI's free database. This Phase 1/2 trial is sponsored by Akeso and is currently Recruiting. The study focuses on Peripheral T-cell Lymphoma. Target enrollment is 80 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.